Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The firm connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. The company has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.
MGRX'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Mangoceuticals Inc'in en son EPS'si $ olup, $ beklentilerini .
Mangoceuticals Inc MGRX'ün son çeyrekteki geliri nasıl performans gösterdi?
Mangoceuticals Inc'in son çeyrek geliri $
Mangoceuticals Inc'in gelir tahmini nedir?
Wall Street analistine göre, Mangoceuticals Inc'in gelir tahmini $ ile $ arasında değişmektedir.
Mangoceuticals Inc'in kazanç kalite puanı nedir?
Mangoceuticals Inc'in kazanç kalite puanı B-/29.7667'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
Mangoceuticals Inc kazançlarını ne zaman rapor eder?
Mangoceuticals Inc'in bir sonraki kazanç raporu 2026-06-18'te bekleniyor